S'abonner

Current state of systematic reviews for platelet-rich plasma use in knee osteoarthritis - 26/01/24

Doi : 10.1016/j.otsr.2023.103735 
Gurjovan Sahi a, Jin Tong Du b, Aazad Abbas b, Herman S. Dhotar c, , d
a Faculty of Medicine, University of Toronto, 1 King's College Circle, Toronto, ON, M5S 1A8, Canada 
b Division of Orthopaedic Surgery, University of Toronto, 149 College Street Room 508-A, Toronto, ON, M5T 1P5, Canada 
c Department of Orthopaedic Surgery, North York General Hospital, University of Toronto, 4001 Leslie Street, North York, ON, M2K, Canada 
d Department of Surgery, University of Toronto, 149 College Street 5th Floor, Toronto, ON, M5T 1P5, Canada 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Abstract

Background

Knee osteoarthritis (KOA) is a highly prevalent musculoskeletal disorder affecting millions of people. To date, there is no curative treatment for KOA other than joint arthroplasty. However, treatments such as platelet-rich plasma (PRP) have been proposed as a possible therapy, with increasing interest over the last decade. To date, there are no evidence-based guidelines in the use of PRP therapy for KOA, but there are numerous studies and systematic reviews (SRs) evaluating the usage of PRP in KOA. Since SRs are of great importance for clinical decision-making, it is necessary to access their methodological quality before any valid conclusions can be made. This study will evaluate the methodological quality of SRs on PRP therapy for KOA using a validated assessment tool known as AMSTAR 2, “A MeaSurement Tool to Assess systematic Reviews”.

Hypothesis

It is hypothesized that the methodological quality of SRs will be moderate, whereby most of the SRs will provide an accurate summary of the results but will include more than one critical weakness as defined by the AMSTAR 2 checklist.

Patients and methods

The MEDLINE, EMBASE, PubMed and Cochrane databases were searched from inception to May 2023. Two independent reviewers selected SRs that investigated the use of injection therapies for KOA. Descriptive statistical analysis was performed. AMSTAR 2 assessment was completed independently by the same reviewers. Cohen's kappa was calculated to measure interrater reliability. The quality of the studies was rated as “high”, “moderate”, “low”, and “critically low”. The overall confidence assessment was tabulated.

Results

Forty-one SRs were included in the analysis. The Cohen kappa was 0.88, indicating high interrater reliability. There were no “high” quality SRs identified. Seven SRs (17%) were of “low” quality, while the remainder (34 SRs, 83%) were rated as “critically low”.

Conclusion

The methodological quality of the selected SRs was suboptimal. Clinicians should critically appraise the SRs and interpret their conclusions with caution before making clinical decisions. This study supports future work of high-quality SRs regarding the use of PRP injections for KOA.

Level of evidence

II.

Le texte complet de cet article est disponible en PDF.

Keywords : Platelet-rich plasma, Knee, Osteoarthritis, AMSTAR


Plan


© 2023  Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 110 - N° 1

Article 103735- février 2024 Retour au numéro
Article précédent Article précédent
  • A new magnetic resonance imaging grading system for anterior cruciate ligament myxoid degeneration in osteoarthritis of the knee
  • Yutaka Nakamura, Hiroyasu Ogawa, Katsuhiro Ichikawa, Kazuki Sohmiya, Masaya Sengoku, Tetsuya Shimokawa, Kazuichiro Onishi, Haruhiko Akiyama
| Article suivant Article suivant
  • Minimally invasive cerclage at the tibia using a modified Goetze technique: An anatomical study
  • Stefan Förch, Leonard Lisitano, Franziska von der Helm, Jan Reuter, Edgar Mayr

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.